Multicentric Trial of the Treatment of Huntington's Disease by Cysteamine (RP103)

Inclusion Criteria: * Clinically disease-registered for at least one year, leading to consult (abnormal movements, neuropsychiatric disorders, neuropsychological impairment). * Unified Huntington's Disease Rating Scale motor ≥ 5 * Total Functional Capacity \> 10 (≥ 11) * Huntington Disease diagnosed with abnormal number of CAG repeats: 38 \< nucleotide expansion (CAG) * Age between 18 and 65 * Voluntarily Patient Consent * Patients willing and able to take oral medications, and comply with the specific procedures of the study Exclusion Criteria: * Severe cognitive impairment or neuropsychiatric troubles. * No drug compliance to previous treatment. * Patients with contra indication to the realization of imaging studies (including claustrophobia ) . * Patients who have not given their written and informed consent signed . * No national health insurance affiliation * Private patients of their liberty by judicial or administrative decision, or patients under supervision. * Pregnant women ( pregnancy test will be carried out systematically for women at risk) or lactating . * Women who could become pregnant during the study period and with no contraception. * Patients who have developed hypersensitivity to cysteamine or penicillamine ( against indication of cysteamine ) . * Brain Damage intercurrent MRI. Brain morphological abnormalities , other than those characteristic of the disease . * Disease - associated with neurological repercussions. * Affection - visceral serious , scalable , involving life-threatening. * Mental - disorder may disrupt accession to the Protocol , including a history of spontaneous and / or drug-induced hallucinations history of severe depression that required repeated hospitalizations , history of repeated suicide attempts . * Participation in progress, or interrupted for less than three months, a therapeutic protocol of Huntington's disease . * Patients with a history of surgical interventions to improve the symptoms of Huntington 's disease such as graft neuron, deep brain stimulation, infusion of neurotrophic agent